Recent Updates
Recently added Catalysts
ONCY

CERTIFICATES ex99.htm FORM 52-109F2 CERTIFICATION OF INTERIM FILINGS FULL CERTIFICATE I, Brad Thompson, President and CEO of Oncolytics Biotech Inc., certify the following: 1. Review: I have reviewed the interim financia

Tuesday, November 10, 2009 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Thompson, President and CEO of Oncolytics Biotech Inc., certify the WSLegal\052277\00014\5218666v1 Ball, CFO of Oncolytics Biotech Inc., certify the following: WSLegal\052277\00014\5218666v1

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+48%
120-day peak, hindsight
Typical move
7%
average across 3 past catalysts
Cash runway
~1 mo
High dilution risk
Lead asset
REOLYSIN
Phase 3 · Carcinoma, Squamous Cell of the Head and Neck

Full Press Release Details

Thompson, President and CEO of Oncolytics Biotech Inc., certify the
WSLegal\052277\00014\5218666v1
Ball, CFO of Oncolytics Biotech Inc., certify the following:
WSLegal\052277\00014\5218666v1
ShareAdd on Google
Tags: ONCY Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Nov 10, 2009

Biotech snapshot

Cash runway
$4M liquidity · $3M/mo burn
~1 mo
High dilution risk
Lead asset
REOLYSINPhase 3
Carcinoma, Squamous Cell of the Head and Neck →

Catalyst track record

+48%
best trade around ONCY's most recent catalyst

Peak hindsight return over a 120-day window, across 3 tracked FDA/PDUFA catalysts for ONCY.

See every catalyst's timing & PoA →